Imatinib

Generic Name: Imatinib

Brand Names: Gleevec, Glivec, Imatinib Teva, Imatinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₁N_₇O

CAS Number: 152459-95-5

Unique Ingredient Identifier: BKJ8M8G5HI

Background: Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ...

Indication: Imatinib is indicated for the treatment of adult and pediatric chronic myeloid leukemia with Philadelphia chromosome mutation (Ph+) in blast crisis, accelerated phase, or chronic phase after IFN-alpha therapy failure.Additionally, imatinib is also indicated to treat adult and pediatric Ph+ acute lymphoblastic leukemia, adult myelodysplastic/myeloproliferativ...

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Aggressive Systemic Mastocytosis, Chordomas, Chronic Eosinophilic Leukemia, FIP1L1-PDGFRα fusion kinase status unknown Chronic eosinophilic leukemia, FIP1L1-PDGFRα fusion kinase status unknown Hypereosinophilic syndrome, Gastrointestinal Stromal Tumor (GIST), Hypereosinophilic Syndrome (HES), Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Melanoma, Myelodysplastic Syndrome, Myeloproliferative Disorders (MPD), Refractory Acute Lymphoblastic Leukemia (ALL), Blast phase Chronic myeloid leukemia, CKit mutational status unknown Aggressive systemic mastocytosis, Metastatic Dermatofibrosarcoma protuberans, Newly diagnosed Acute Lymphoblastic Leukaemia, Newly diagnosed, chronic phase Chronic myeloid leukemia, Recurrent Dermatofibrosarcoma protuberans, Refractory, chronic phase Chronic myeloid leukemia, Unresectable Gastrointestinal stromal tumor

Associated Therapies: -

Clinical Trials

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

Phase 4

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Drug: Prednisolone
Drug: Dexamethasone
Drug: L-Asparaginase
Drug: Vincristine
Drug: Methotrexate
Drug: Doxorubicin
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: 6-Mercaptopurine
Drug: Cytarabine
Drug: Thioguanine
Drug: Fludarabine
Drug: Imatinib

First Posted Date: 2016-09-09

Last Posted Date: 2016-09-30

Lead Sponsor: National University Hospital, Singapore

Target Recruit Count: 500

Registration Number: NCT02894645

Locations: 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾
Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬
National University Hospital, Singapore, Singapore

and more 1 locations

Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

First Posted Date: 2016-08-26

Last Posted Date: 2024-10-10

Lead Sponsor: Goethe University

Target Recruit Count: 1000

Registration Number: NCT02881086

Locations: 🇩🇪
University Hospital of Frankfurt (Main), Frankfurt (Main), Germany

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia, Influenza, COVID-19

Interventions: Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Moxifloxacin or Levofloxacin
Drug: Extended course macrolide
Drug: Fixed-duration Hydrocortisone
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Eritoran
Drug: Cysteamine
Drug: Imatinib
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Angiotensin Receptor Blockers
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Intermediate dose thromboprophylaxis
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Amoxicillin-clavulanate
Drug: Fixed-duration dexamethasone
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil

First Posted Date: 2016-04-13

Last Posted Date: 2024-07-12

Lead Sponsor: UMC Utrecht

Target Recruit Count: 20000

Registration Number: NCT02735707

Locations: 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸
University of Illinois Health, Chicago, Illinois, United States
🇦🇺
Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy

Phase 2

Terminated

Conditions: Colonic Neoplasms

Interventions: Drug: Imatinib

First Posted Date: 2016-02-18

Last Posted Date: 2019-10-14

Lead Sponsor: UMC Utrecht

Target Recruit Count: 5

Registration Number: NCT02685046

Locations: 🇳🇱
Diakonessenhuis, Utrecht, Netherlands
🇳🇱
Meander Medical Center, Amersfoort, Utrecht, Netherlands
🇳🇱
University Medical Center Utrecht, Utrecht, Netherlands

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

First Posted Date: 2015-12-23

Last Posted Date: 2020-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 90

Registration Number: NCT02638428

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults

Phase 3

Recruiting

Conditions: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia

Interventions: Drug: Nilotinib
Drug: Methotrexate
Drug: Aracytine (Ara C)
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
Drug: Depomedrol
Drug: Dexamethasone
Drug: Vincristine
Drug: Imatinib
Drug: 6 Mercaptopurine (6MP)

First Posted Date: 2015-11-20

Last Posted Date: 2019-10-21

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 265

Registration Number: NCT02611492

Locations: 🇫🇷
Hopital Saint Louis, Paris, France

Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia

Phase 4

Conditions: Chronyc Myeloid Leukemia

Interventions: Drug: Imatinib
Drug: Nilotinib

First Posted Date: 2015-11-11

Last Posted Date: 2022-01-20

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 450

Registration Number: NCT02602314

Locations: 🇮🇹
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
🇮🇹
UO Ematologia con trapianto-Università degli Studi di Bari Aldo Moro, Bari, Italy
🇮🇹
Ausl Della Romagna, Ospedale "Infermi" - Rimini - Uo Ematologia, Rimini, Italy

and more 79 locations